Daily briefings
Editor’s Briefing: November 16, 2026
In Short. The FDA did not approve Summit's ivonescimab in lung cancer. AstraZeneca's Imfinzi was approved for bladder cancer. Cytokinetics updated MYQORZO's label versus a beta blocker. Aclaris said bosakitug missed its trial goal.
The FDA declines to approve Summit's ivonescimab in a form of lung cancer
NON-SMALL CELL lung cancer is the most common form of lung cancer. Some of those tumors carry a change in a growth-signal gene called EGFR and are first treated with medicines that block that signal. On Sunday Summit Therapeutics said the Food and Drug Administration had issued a complete response letter for ivonescimab used with platinum chemotherapy (announcement). That letter is the agency's formal notice that a biologic application cannot be approved in its present form. The intended use was locally advanced or metastatic disease after prior EGFR inhibitor treatment. Ivonescimab is an experimental antibody meant to block two proteins at once: PD-1, which some tumors use to evade immune attack, and VEGF, which helps tumors grow blood vessels.
The application rested on HARMONi, a Phase 3 trial of ivonescimab plus chemotherapy versus placebo plus chemotherapy. The trial had two main goals: how long people lived without the cancer worsening, and how long they lived overall. It met the first of those goals. It did not show a statistically significant improvement in overall survival. The FDA said that improvement was needed to establish substantial evidence of effectiveness. Sixteen people stopped ivonescimab because of treatment-related unwanted effects, compared with 11 who stopped placebo.
AstraZeneca's Imfinzi combination is approved for muscle-invasive bladder cancer
MUSCLE-INVASIVE bladder cancer is cancer that has grown into the muscle wall of the bladder. On Friday the FDA approved AstraZeneca's Imfinzi (durvalumab) with enfortumab vedotin before surgery to remove the bladder, then Imfinzi alone afterward (announcement). The approval is for adults who cannot have or have declined cisplatin chemotherapy. Imfinzi is an antibody that blocks PD-L1, a protein tumors use to dampen immune attack. Enfortumab vedotin delivers a cell-killing drug.
The approval is based on VOLGA, a Phase 3 trial that assigned 695 people at random, in equal groups, to three arms. The comparator was bladder-removal surgery with or without approved treatment after surgery. The main measure was a composite of the cancer worsening or coming back, the person not having surgery, or death. In a planned interim analysis, the Imfinzi combination reduced that risk by 49% versus the comparator (hazard ratio 0.51, 95% confidence interval 0.38 to 0.67, p<0.0001). An estimated 64% of people on the Imfinzi combination were alive and without those events at two years, compared with 45% in the comparator arm. The risk of death was 42% lower (hazard ratio 0.58, 95% confidence interval 0.40 to 0.83, p=0.0027).
Cytokinetics adds a beta-blocker comparison to the MYQORZO label
HYPERTROPHIC CARDIOMYOPATHY is a disease in which the heart muscle becomes abnormally thick. In the obstructive form, the thickening can block blood flow leaving the heart. On Monday Cytokinetics said the FDA had approved a supplement to the US prescribing information for MYQORZO (aficamten) (announcement). The update adds data from MAPLE-HCM, a Phase 3 trial that compared MYQORZO with the beta blocker metoprolol, each used alone, in adults with symptomatic obstructive disease. MYQORZO is a cardiac myosin inhibitor, a medicine that lessens the force of the heart's contraction. It was first approved in December 2025.
MAPLE-HCM met its main goal, a change in peak oxygen uptake from the start of the trial to week 24, and the medicine also improved five of six secondary goals. The label carries a boxed warning that MYQORZO can lower the heart's pumping fraction and can cause heart failure. It is available only through a restricted safety program, and heart imaging is required before and during treatment.
Aclaris reports that bosakitug missed its main goal in a mid-stage eczema trial
ATOPIC DERMATITIS, also called eczema, is a chronic inflammatory skin disease. On Monday Aclaris Therapeutics reported results from ADMIRATION, a Phase 2 trial of bosakitug in people with moderate to severe disease (announcement). Bosakitug is an experimental antibody designed to block thymic stromal lymphopoietin, or TSLP, a signaling protein that can drive skin inflammation. The main goal was the percent change at week 24 in the Eczema Area and Severity Index, a standard score of how widespread and severe the rash is. The trial did not meet that goal, and it did not meet its secondary goals. The company said TSLP was engaged and that bosakitug was generally well tolerated.
What to watch
By November 22 the FDA is due to decide on Capricor's deramiocel for Duchenne muscular dystrophy, and on Savara's inhaled molgramostim. A decision on BridgeBio's BBP-418 is due on November 27.